An Open-Label, Prospective, Pilot Study of Hypertonic Saline for Hidradenitis Suppurativa.

Autor:	Porter ML; Clinical Laboratory for Epidemiology and Applied Research in Skin, Harvard Medical School, Boston, Massachusetts., Salian P; Clinical Laboratory for Epidemiology and Applied Research in Skin, Harvard Medical School, Boston, Massachusetts., Rosales Santillan M; Clinical Laboratory for Epidemiology and Applied Research in Skin, Harvard Medical School, Boston, Massachusetts.; Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts., Greif C; Clinical Laboratory for Epidemiology and Applied Research in Skin, Harvard Medical School, Boston, Massachusetts., Kimball AB; Clinical Laboratory for Epidemiology and Applied Research in Skin, Harvard Medical School, Boston, Massachusetts.
Jazyk:	angličtina
Zdroj:	Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] [Dermatol Surg] 2022 Sep 01; Vol. 48 (9), pp. 954-960. Date of Electronic Publication: 2022 Aug 09.
DOI:	10.1097/DSS.0000000000003510
Abstrakt:	Background: Hidradenitis suppurativa (HS) fistulas are likely to persist without surgical intervention. Hypertonic saline (HTS), a venous sclerosant, disrupts the endothelial lining leading to occlusion and fibrosis when used for venous insufficiency. Objective: To evaluate the efficacy and tolerability of HTS sclerotherapy for HS fistulas. Methods and Materials: This Institutional review board-approved, nonrandomized, clinical trial included adult patients with a diagnosis of HS and at least one confirmed HS fistula who underwent HTS injections into their fistulas every two weeks followed by a 4-week follow-up period. The study was performed from 2016 to 2019 at two academic outpatient dermatology clinics in Boston, MA. Primary outcomes were physician-assessed improvement of HS fistula characteristics between final and baseline visits and physician-assessed HS improvement during course of study. Results: Overall, 21 patients participated. Physician-assessed overall HS improvement was significant between Visits 2 and 3 (p = .036). Drainage (p = .035), erythema (p = .008), and swelling (p = .025) demonstrated statistically significant improvement from baseline to final visit. Dermatology life quality index scores significantly improved from baseline to Visit 2 (p = .0005), Visit 3 (p = .0008), and final visit (p = .011). Numeric rating scale stinging scores increased with sclerosant volume. Conclusion: This study demonstrated physician-reported and patient-reported improvement in fistulas following serial HTS injections. HTS injections were well tolerated. (Copyright © 2022 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu